Article Sidebar
Published:
Jun 2, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of MiR-181a as a potential therapeutic target in osteoarthritis
Abstract
Purpose: To investigate microRNA-181 (miR-181) as a potential therapeutic target in osteoarthritis (OA).
Methods: MiR-181 expression was evaluated in articular cartilage samples obtained from OA patients undergoing knee arthroplasty and non-OA (control) patients undergoing other orthopedic procedures. Following the isolation of total RNA, miRNA and mRNA expression was determined by real timepolymerase chain reaction (RT-PCR). Luciferase reporter assay and miRNA mimic or inhibitor were then used to establish the molecular target of miR-181 in chondrocytes.
Results: miR-181 family members, namely, miR-181a, miR-181c and miR-181d were significantly upregulated in articular cartilage obtained from OA patients compared to non-OA control subjects. However, no significant difference in up-regulation of miR-181b expression. B-cell lymphoma 2 (BCL2), a putative target of the miR-181 family, was significantly down-regulated in OA patients compared to control subjects. Furthermore, luciferase reporter assay confirmed direct interaction between miR-181a and three prime untranslated region The 3’UTR of BCL2 in chondrocytes. Transfection of miR-181 mimic resulted in BCL2 suppression in chondrocytes. On the other hand, transfection of miR-181 inhibitor led to increased BCL2 expression and decreased interleukin 1-beta (IL1-β) induced apoptosis.
Conclusion: miR-181 is differentially expressed in articular cartilage of OA patients and leads to downregulation of BCL2, a regulator of apoptosis. Therefore, miR-181 may be a potential therapeutic target in the treatment of OA.
Keywords: MicroRNA, Osteoarthritis, Apoptosis, B-cell lymphoma 2, Transfection, Chondrocytes
